Gastrointestinal Cancer

Latest News

Latest Videos

Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.

Ghassan K. Abou-Alfa, MD, Spotlights Patients With Unresectable HCC Who May Best Benefit From Tremelimumab/Durvalumab

Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.

Ghassan K. Abou-Alfa, MD, Discusses Importance of Treatment Accessibility in Unresectable HCC

Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.

Ghassan K. Abou-Alfa, MD, Highlights Approval of Tremelimumab and Durvalumab in Unresectable HCC

Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.

Howard A. Burris, MD, Talks QOL With Durvalumab/Chemo in Advanced Biliary Tract Cancer From TOPAZ-1 Trial

Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.

Shubham Pant, MD, Highlights Outcomes With Erdafitinib in Gastrointestinal Cancers

Sam Klempner, MD, Looks at Broad Use of ctDNA in Oncology

Sam Klempner, MD, Talks ctDNA for Nonmetastatic Gastric and Esophageal Cancers

Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers

Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers

Yelena Y. Janjigian, MD, Reviews MSI as a Biomarker in for Localized Gastric Cancer

CME Content

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Iowa

Sapna Patel, MD; Rakesh Bagai, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | New York

Yana G. Najjar, MD; Deepa Jagtap, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Minnesota

Yana G. Najjar, MD; Anand Patel, MD

In-Person Event

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Texas

Yana G. Najjar, MD; Kara Schenk, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Washington

Yana G. Najjar, MD; Albert Dekker, MD

Video

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD

Multimedia

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Multimedia

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA

Multimedia

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD

Multimedia

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD

Multimedia

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA

Video

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Multimedia

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Kathleen N. Moore, MD, MS, FASCO; Prof Susana Banerjee, MBBS, MA, FRCP, PhD

Video

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Louisiana

Jacob Sands, MD; Uday Dandamudi, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Colorado

Sapna Patel, MD; Jyothi Dodlapati, MD

Video

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Montana and Wyoming

Jacob Sands, MD; Brian Vicuna, MD

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

In-Person + Virtual Event

Breast Cancer Symposia in San Antonio

December 8-11, 2025

Multimedia

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Jae H. Park, MD

Virtual Event

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

December 19, 2025

Multimedia

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Tiffany A. Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH

Video

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Mark Agulnik, MD; Shaina A. Rozell, MD, MPH

Video

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Lee M. Zuckerman, MD

Multimedia

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Daniel Lefler, MD; Shaina A. Rozell, MD, MPH; Lee M. Zuckerman, MD

Case-based Simulation

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Mark Agulnik, MD; Daniel Lefler, MD

In-Person Event

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

January 22, 2026

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Video

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Naval G. Daver, MD; Jessica Altman, MD; Amir T. Fathi, MD; Gail J. Roboz, MD; Joshua Zeidner, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

More News

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC

ByRoman Fabbricatore

January 27th 2025

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC

ByJax DiEugenio

January 27th 2025

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

Pembrolizumab Combo Does Not Meet OS End Point in Advanced Gastric Cancer

ByRoman Fabbricatore

January 27th 2025

Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.

Long-term Aspirin Use Decreased PIK3CA-Mutated Colorectal Cancer Recurrence

ByKristie L. Kahl

January 26th 2025

The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.

Balstilimab Plus Botensilimab Enhances Response in MSS mCRC without Liver Mets

ByKristi Rosa

January 26th 2025

A phase 2 study evaluated the efficacy of balstilimab and botensilimab in patients with MSS metastatic mCRC without liver metastases.

Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer treated in the BESPOKE trial.

ctDNA Shows High Recurrence Detection Sensitivity in Stage II/III CRC

ByRoman Fabbricatore

January 26th 2025

Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer treated in the BESPOKE trial.

Updated results support nivolumab/ipilimumab as a standard of care in patients with MSI-H or dMMR metastatic colorectal cancer.

Nivolumab/Ipilimumab Extends PFS in MSI-H/dMMR Metastatic Colorectal Cancer

ByRuss Conroy

January 25th 2025

Updated results support nivolumab/ipilimumab as a standard of care in patients with MSI-H or dMMR metastatic colorectal cancer.

The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.

Palliative Care May Improve EOL Comfort in Early-Onset Colorectal Cancer

ByRoman Fabbricatore

January 25th 2025

The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.

Synchronous metastatic status does not appear to affect survival among patients with resected BRAF V600E-mutated metastatic colorectal cancer.

Real-World Data Show Poor Outcomes in BRAF V600E-Mutant Metastatic CRC

ByRuss Conroy

January 25th 2025

Synchronous metastatic status does not appear to affect survival among patients with resected BRAF V600E-mutated metastatic colorectal cancer.

Neoadjuvant Pembrolizumab Enhances Response in dMMR Colon Cancer

ByAriana Pelosci

January 25th 2025

A pCR rate of 44% was observed when neoadjuvant pembrolizumab was given to patients with dMMR colon cancer.

Post hoc analysis of the phase 3 NAPOLI 3 trial assessed how dose reductions in liposomal irinotecan/oxaliplatin affect OS in NALIRIFOX-treated PDAC.

Lower Liposomal Irinotecan/Oxaliplatin Doses Do Not Worsen PDAC Outcomes

ByJax DiEugenio

January 25th 2025

Post hoc analysis of the phase 3 NAPOLI 3 trial assessed how dose reductions in liposomal irinotecan/oxaliplatin affect OS in NALIRIFOX-treated PDAC.

SCRT Followed by Cadonilimab/Chemo Shows Responses in pMMR/MSS Rectal Cancer

ByTim Cortese

January 25th 2025

The NeoCaCRT trial found that SCRT followed by cadonilimab and mFOLFOX6 elicited a pCR of 37.0%, meeting its primary end point for patients with locally advanced rectal cancer.

A 3-cohort retrospective analysis compared patients who met eligibility for the NAPOLI 3 trial with all-comers treated with FOLFIRINOX for PDAC.

NALIRIFOX Numerically Improves OS Vs FOLFIRINOX in Metastatic PDAC

ByRoman Fabbricatore

January 25th 2025

A 3-cohort retrospective analysis compared patients who met eligibility for the NAPOLI 3 trial with all-comers treated with FOLFIRINOX for PDAC.

Findings highlight the challenge of evolving logistics for testing and related decision-making in the treatment of those with gastric or GEJ cancers.

Data Show Inconsistent Biomarker Testing in Gastric/GEJ Cancer Care

ByBridget Hoyt

January 25th 2025

Findings highlight the challenge of evolving logistics for testing and related decision-making in the treatment of those with gastric or GEJ cancers.

ctDNA Status Predicts DFS Benefit of Celecoxib in Stage III Colon Cancer

ByAshling Wahner

January 25th 2025

Subgroup analysis of the CALGB/SWOG 80702 trial investigated the impact of ctDNA status on DFS in stage III resected colon cancer patients treated with celecoxib or placebo.

CRT Plus Chemo Did Not Improve RFS in Resected Gallbladder Cancer

ByAriana Pelosci

January 25th 2025

Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.

The phase 2 EA2186 trial was the first elderly-specific clinical trial evaluating chemotherapy in vulnerable adults with metastatic pancreatic cancer.

Baseline Geriatric and QOL Factors Linked to Chemotherapy Survival in PDAC

ByRoman Fabbricatore

January 24th 2025

The phase 2 EA2186 trial was the first elderly-specific clinical trial evaluating chemotherapy in vulnerable adults with metastatic pancreatic cancer.

Pamrevlumab Combo Does Not Improve Survival in Advanced Pancreatic Cancer

ByAriana Pelosci

January 24th 2025

Results from the phase 3 LAPIS trial showed pamrevlumab/chemotherapy did not improve survival vs placebo/chemotherapy in locally advanced, unresectable pancreatic cancer.

Nivolumab/Ipilimumab Yielded Superior Efficacy and Safety Data in uHCC

ByJordyn Sava

January 24th 2025

Nivolumab plus ipilimumab generated an ORR of 36% vs 13% from levantinib plus sorafenib in unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Updated phase 2 results support further investigation of surufatinib plus TAS-012 in a larger cohort of patients with pancreatic ductal adenocarcinoma.

Later-Line Surufatinib Combo Shows Promising Activity in Metastatic PDAC

ByRuss Conroy

January 24th 2025

Updated phase 2 results support further investigation of surufatinib plus TAS-012 in a larger cohort of patients with pancreatic ductal adenocarcinoma.

Patients With Extrapancreatic NETs Experience Improved PFS from Cabozantinib

ByMegan Hollasch

January 24th 2025

Patients who received cabozantinib experienced a PFS of 8.5 months vs 5.6 months with placebo, a subgroup analysis from the CABINET trial found.

Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.

TACE Plus Camrelizumab/Rivoceranib Extends PFS in Unresectable Liver Cancer

ByRuss Conroy

January 24th 2025

Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.

Sintilimab Plus CRT Yields Superior Responses in Resectable, Locally Advanced ESCC

ByChris Ryan

January 24th 2025

Sintilimab plus neoadjuvant chemoradiotherapy yielded a pCR rate of 60% vs 13% from sintilimab plus chemotherapy in patients with locally advanced ESCC.

Tislelizumab/Chemo Demonstrates Promising Activity in Gastric/GEJ Cancer

ByCaroline Seymour

January 24th 2025

Phase 1/2 SYLT-023 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in patients with advanced, HER2-negative, mismatch repair–proficient gastric/GEJ cancer.

Trastuzumab Combo Shows Nonsignificant Advantages in Gastric/GEJ Cancer

ByRuss Conroy

January 24th 2025

Adding trastuzumab and pertuzumab to chemotherapy conferred higher toxicity among patients with HER2-positive gastric cancers in the INNOVATION trial.